 |
Gilead, Achillion initiate phase I trial evaluating GS 9132 for treatment of hep C
Monday, August 22, 2005 14:00 IST
Foster City, CA
Gilead Sciences and Achillion Pharmaceuticals have begun dosing patients in a Phase I study of GS 9132, also known as ACH-806
Read complete story ...
(You will need to login first to read this story.)
|
|
|
